Literature DB >> 2158548

Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment.

F H Noormohamed1, W R McNabb, A F Lant.   

Abstract

The pharmacokinetic and pharmacodynamic profiles of oral enalapril (20 mg), in absence and in presence of probenecid pretreatment (1 g twice daily for 5 days), were investigated in 12 healthy volunteers on normal salt intake (150 mmol/24 hr). Mean peak serum concentration of enalapril rose from 158 +/- 7 to 216 +/- 1 ng/ml (P less than .01), whereas that of its metabolite, enalaprilat, rose from 62 +/- 6 to 84 +/- 8 ng/ml (P less than .01) in the presence of probenecid pretreatment. Area under the curve of both enalapril and enalaprilat increased by 50% (P less than .001), which was accompanied by a reduction in renal excretion of both compounds. The renal clearance of enalapril decreased from 229 +/- 19 to 61 +/- 4 ml/min (P less than .001) and that of enalaprilat from 108 +/- 4 to 66 +/- 2 ml/min (P less than .001). The total drug recovery fell from 48 +/- 3 to 38 +/- 2% (P less than .01) of the administered dose with no accompanying changes in plasma elimination half-lives of the parent drug or metabolite. The pharmacodynamic response of enalapril such as fractional excretions of sodium, calcium, magnesium and urate were enhanced by probenecid pretreatment. Absolute urinary excretion of sodium increased from 51 +/- 5 to 91 +/- 8 mmol/6 hr (P less than .001) after enalapril and from 55 +/- 4 to 113 +/- 13 mmol/6 hr (P less than .01) after enalapril in presence of probenecid pretreatment, despite a significant decrease in the renal excretion of enalapril and enalaprilat over the same interval.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158548

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Tubular transport mechanisms of quinapril and quinaprilat in the isolated perfused rat kidney: effect of organic anions and cations.

Authors:  A R Kugler; S C Olson; D E Smith
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

2.  Organ clearance concepts: new perspectives on old principles.

Authors:  G L Sirianni; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

Review 3.  Fosinopril. Clinical pharmacokinetics and clinical potential.

Authors:  H Shionoiri; M Naruse; K Minamisawa; S Ueda; H Himeno; S Hiroto; I Takasaki
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

4.  Competitive inhibition of p-aminohippurate transport by quinapril in rabbit renal basolateral membrane vesicles.

Authors:  W Akarawut; D E Smith
Journal:  J Pharmacokinet Biopharm       Date:  1998-06

Review 5.  Ontogeny of drug elimination by the human kidney.

Authors:  Nancy Chen; Katarina Aleksa; Cindy Woodland; Michael Rieder; Gideon Koren
Journal:  Pediatr Nephrol       Date:  2005-12-06       Impact factor: 3.714

6.  Analysis of the natriuretic action of a loop diuretic, piretanide, in man.

Authors:  F H Noormohamed; A F Lant
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

Review 7.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

8.  Tailored Assays for Pharmacokinetic and Pharmacodynamic Investigations of Aliskiren and Enalapril in Children: An Application in Serum, Urine, and Saliva.

Authors:  Bjoern B Burckhardt; Jutta Tins; Sergej Ramusovic; Stephanie Läer
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Nov-Dec

9.  A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system.

Authors:  Karina Claassen; Stefan Willmann; Thomas Eissing; Tobias Preusser; Michael Block
Journal:  Front Physiol       Date:  2013-02-08       Impact factor: 4.566

10.  Identification of Structural Features for the Inhibition of OAT3-Mediated Uptake of Enalaprilat by Selected Drugs and Flavonoids.

Authors:  Yao Ni; Zelin Duan; Dandan Zhou; Shuai Liu; Huida Wan; Chunshan Gui; Hongjian Zhang
Journal:  Front Pharmacol       Date:  2020-05-28       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.